Syntropic Medical funding news – Vienna-based Syntropic Medical Secures €1.1 Million in Funding

The business was founded by Prof. Sandra Siegert, Dr. Alessandro Venturino, Jack O'Keeffe, and Mark Caffrey and was spun out of the Institute of Science and Technology Austria (ISTA).

Read Also - Nscale Acquisition News -Nscale Acquires Kontena to Enhance HPC and AI Infrastructure Capabilities

The Siegert Group at ISTA developed a light stimulation protocol that serves as the foundation for Syntropic's innovative light-based brain stimulation device. By stimulating the brain in a way that encourages microglia-mediated neuroplasticity, they can potentially cure a variety of neuropsychiatric conditions, including Major Depressive Disorder (MDD). By doing this, Syntropic hopes to give patients who have not responded adequately to conventional pharmaceutical medicines an alternative course of treatment.

Mark Caffrey, Syntropic CEO said, “Approximately 70 per cent of patients taking pharmaceutical antidepressants will fail to achieve remission, and up to 25 per cent will stop taking them due to the severity of side effects. These numbers are unfortunately not good enough. Therefore, it is crucial that we begin to develop completely new methods of tackling these disorders. This is why the discoveries of Dr Venturino and Prof Siegert are so exciting, they open the potential for an entirely new modality of treatment that is side effect free and easily accessible for the patient,”.

About Syntropic

Syntropic is a medical device firm in the pre-clinical stage that is creating new technologies to boost neuroplasticity in the brain, which can be used to treat mental illnesses and improve cognitive function.